search
Back to results

Integral Strategy to Supportive Care in Breast Cancer Patients

Primary Purpose

Breast Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
BENECA System
Supervised-occupational therapy program
Sponsored by
Universidad de Granada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Neoplasms focused on measuring Breast Neoplasms, survivor, occupational therapy, mobile applications, Quality of Life

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of stage I, II or IIIA breast cancer.
  • Overweight or obese, according to the Spanish Society for the Study of Obesity.
  • Basic ability to use mobile apps or living with someone who has this ability.
  • Medical clearance of participants.
  • Completion of adjuvant therapy except for hormone therapy.
  • Some functional or Range of Motion (ROM) limitations measures by goniometry and the DASH Questionnaire.
  • Have signed informed consent.

Exclusion Criteria:

  • History of cancer recurrence.
  • Chronic disease or orthopedic issues that would interfere with the ability to participate in the rehabilitation program.
  • Uncontrolled hypertension (diastolic pressure > 95mm Hg).

Sites / Locations

  • Faculty of Health Sciences. University of Granada

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

m-Health group

Integral Group

Arm Description

BENECA System: The m-health group will use the BENECA app for 8 weeks.

BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.

Outcomes

Primary Outcome Measures

Quality of life (QLQ)
The primary outcome will be assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORT QLQ-C30) version 3.0., and with the European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (EORT QLQ-BR23). Both are the most widely used instruments to measure Quality of Life in cancer patients.

Secondary Outcome Measures

Body mass Index
Body mass index, in kg/m2, will be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Fat mass
% Fat mass will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Abdominal adipose tissue
Abdominal adipose tissue will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Bone mineral density
Bone mineral density (Z-score) will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Shoulder Range of Motion (ROM)
- Shoulder ROM measurements will be obtained using a standard, two-armed goniometer which is described as the clinical gold standard.
Upper Body Functionality
The disability of the arm, shoulder and hand (DASH) questionnaire will be used to measure the upper extremity functionality. It includes 30-item disability/symptom scale.
Upper body muscular strength
Handgrip: Upper body muscular strength will be determined using digital dynamometer (TKK 5101 Grip-D; Tokyo, Japan. The precision will be 0.1 kg.
Cognitive function: attention
The trial making test (TMT) will be used to assess speed for attention, sequencing, mental flexibility, visual search and motion function.
Cognitive function: memory and processing speed
Wechsler Adult Intelligence Scale (WAIS IV) will be used to assess working memory and processing speed.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) will be used to assess levels of anxiety and depression. It contains 14 items (7 items for each scale) with 4-point likert scale.
Physical activity
Participants will be asked to wear an try-axial accelerometer (ActiGraph GT3X+, Pensacola, Florida, US) to record physical activity intensity levels and patterns, as well as sleeping habits.

Full Information

First Posted
June 22, 2016
Last Updated
October 24, 2017
Sponsor
Universidad de Granada
Collaborators
Carlos III Health Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02817724
Brief Title
Integral Strategy to Supportive Care in Breast Cancer Patients
Official Title
Integral Strategy to Supportive Care in Breast Cancer Patients Through Occupational Therapy and a M-health System: a Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Granada
Collaborators
Carlos III Health Institute

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine if it is better an integral strategy, with a m-health system, when used in addition to a supervised treatment, versus the use of the m-health system alone, to improve the immediate and long-term Quality of Life of breast cancer survivors.
Detailed Description
Background: Technological support using e-health mobile applications (m-health) is a promising strategy to improve the adherence to healthy lifestyles in breast cancer survivors (excess in energy intake or low physical activity are determinants of the risk of recurrence, second cancers and cancer mortality). Moreover, cancer rehabilitation programs supervised by health professionals are needed due to the inherent characteristics of these breast cancer patients. Our main objective is to compare the clinical efficacy of a m-health lifestyle intervention system alone versus an integral strategy to improve Quality of Life (QoL) in breast cancer survivors. Methods: This therapeutic superiority study will use a two-arm, assessor blinded parallel randomized clinical trial (RCT) design. Women will be eligible if: they are diagnosed of stage I, II or III-A breast cancer; are between 25 and 75 years old; have a Body Mass Index > 25kg/m2; they have basic ability to use mobile apps; they had completed adjuvant therapy except for hormone therapy; and they have some functional shoulder limitations. Participants will be randomized to one of the following groups: integral group will use a mobile application (BENECA APP) and will receive a supervised rehabilitation (8-weeks); m-health group will use the BENECA app for 8-weeks. Study endpoints will be assessed after 8 weeks and 24 weeks. The primary outcome will be QoL measured by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core and breast module. The secondary outcomes: body composition; upper-body functionality (handgrip, Disability of the Arm, Shoulder and Hand questionnaire, goniometry); cognitive function (Wechsler Adult Intelligence Scale, Trial Making Test); anxiety and depression (Hospital Anxiety and Depression Scale); and accelerometer. Discussion: This study has been designed to seek to address the new needs for support and treatment of breast cancer survivors, reflecting the emerging need to merge new low cost treatment options with much-needed involvement of health professionals in this type of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms
Keywords
Breast Neoplasms, survivor, occupational therapy, mobile applications, Quality of Life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
m-Health group
Arm Type
Active Comparator
Arm Description
BENECA System: The m-health group will use the BENECA app for 8 weeks.
Arm Title
Integral Group
Arm Type
Experimental
Arm Description
BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
Intervention Type
Device
Intervention Name(s)
BENECA System
Intervention Description
BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
Intervention Type
Other
Intervention Name(s)
Supervised-occupational therapy program
Intervention Description
It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
Primary Outcome Measure Information:
Title
Quality of life (QLQ)
Description
The primary outcome will be assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORT QLQ-C30) version 3.0., and with the European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (EORT QLQ-BR23). Both are the most widely used instruments to measure Quality of Life in cancer patients.
Time Frame
Participants will be followed over 8 weeks.
Secondary Outcome Measure Information:
Title
Body mass Index
Description
Body mass index, in kg/m2, will be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Time Frame
Participants will be followed over 8 weeks.
Title
Fat mass
Description
% Fat mass will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Time Frame
Participants will be followed over 8 weeks.
Title
Abdominal adipose tissue
Description
Abdominal adipose tissue will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Time Frame
Participants will be followed over 8 weeks.
Title
Bone mineral density
Description
Bone mineral density (Z-score) will also be assessed by conducting Dual-energy X-ray absorptiometry (DXA, Discovery densitometer from HOLOGIC, QDR 4500W).
Time Frame
Participants will be followed over 8 weeks.
Title
Shoulder Range of Motion (ROM)
Description
- Shoulder ROM measurements will be obtained using a standard, two-armed goniometer which is described as the clinical gold standard.
Time Frame
Participants will be followed over 8 weeks.
Title
Upper Body Functionality
Description
The disability of the arm, shoulder and hand (DASH) questionnaire will be used to measure the upper extremity functionality. It includes 30-item disability/symptom scale.
Time Frame
Participants will be followed over 8 weeks.
Title
Upper body muscular strength
Description
Handgrip: Upper body muscular strength will be determined using digital dynamometer (TKK 5101 Grip-D; Tokyo, Japan. The precision will be 0.1 kg.
Time Frame
Participants will be followed over 8 weeks.
Title
Cognitive function: attention
Description
The trial making test (TMT) will be used to assess speed for attention, sequencing, mental flexibility, visual search and motion function.
Time Frame
Participants will be followed over 8 weeks.
Title
Cognitive function: memory and processing speed
Description
Wechsler Adult Intelligence Scale (WAIS IV) will be used to assess working memory and processing speed.
Time Frame
Participants will be followed over 8 weeks.
Title
Anxiety and depression
Description
The Hospital Anxiety and Depression Scale (HADS) will be used to assess levels of anxiety and depression. It contains 14 items (7 items for each scale) with 4-point likert scale.
Time Frame
Participants will be followed over 8 weeks.
Title
Physical activity
Description
Participants will be asked to wear an try-axial accelerometer (ActiGraph GT3X+, Pensacola, Florida, US) to record physical activity intensity levels and patterns, as well as sleeping habits.
Time Frame
Participants will be followed over 8 weeks.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of stage I, II or IIIA breast cancer. Overweight or obese, according to the Spanish Society for the Study of Obesity. Basic ability to use mobile apps or living with someone who has this ability. Medical clearance of participants. Completion of adjuvant therapy except for hormone therapy. Some functional or Range of Motion (ROM) limitations measures by goniometry and the DASH Questionnaire. Have signed informed consent. Exclusion Criteria: History of cancer recurrence. Chronic disease or orthopedic issues that would interfere with the ability to participate in the rehabilitation program. Uncontrolled hypertension (diastolic pressure > 95mm Hg).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manuel Arroyo-Morales, PhD
Organizational Affiliation
Deparment of physiotherapy, Faculty of Health Sciences, University of Granada
Official's Role
Study Director
Facility Information:
Facility Name
Faculty of Health Sciences. University of Granada
City
Granada
ZIP/Postal Code
18071
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
29588273
Citation
Lozano-Lozano M, Galiano-Castillo N, Martin-Martin L, Pace-Bedetti N, Fernandez-Lao C, Arroyo-Morales M, Cantarero-Villanueva I. Monitoring Energy Balance in Breast Cancer Survivors Using a Mobile App: Reliability Study. JMIR Mhealth Uhealth. 2018 Mar 27;6(3):e67. doi: 10.2196/mhealth.9669.
Results Reference
derived
PubMed Identifier
27887610
Citation
Lozano-Lozano M, Martin-Martin L, Galiano-Castillo N, Alvarez-Salvago F, Cantarero-Villanueva I, Fernandez-Lao C, Sanchez-Salado C, Arroyo-Morales M. Integral strategy to supportive care in breast cancer survivors through occupational therapy and a m-health system: design of a randomized clinical trial. BMC Med Inform Decis Mak. 2016 Nov 25;16(1):150. doi: 10.1186/s12911-016-0394-0.
Results Reference
derived

Learn more about this trial

Integral Strategy to Supportive Care in Breast Cancer Patients

We'll reach out to this number within 24 hrs